| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.006 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.076 | 0.007 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.009 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.092 | 0.009 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.12 | 0.01 |